Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A, Nieves HC, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. Canella A, et al. Oncotarget. 2023 Sep 25;14:837-838. doi: 10.18632/oncotarget.28515. Oncotarget. 2023. PMID: 37747363 Free PMC article. No abstract available.
Most multiple myeloma patients have low testosterone.
John S, Sharma N, Sborov DW, Williams N, Jones D, Benson DM, Efebera YA, Rosko AE, Vincent J, Hofmeister CC. John S, et al. Among authors: sborov dw. Leuk Lymphoma. 2019 Mar;60(3):836-838. doi: 10.1080/10428194.2018.1508664. Epub 2018 Oct 2. Leuk Lymphoma. 2019. PMID: 30277092 Free PMC article. No abstract available.
Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up.
Sharma N, Chen DT, Zhao Q, Williams NY, Rosko A, Benson DM, Chaudhry M, Bumma N, Khan A, Devarakonda S, Hofmeister CC, Sborov D, Efebera YA. Sharma N, et al. Among authors: sborov d. Biol Blood Marrow Transplant. 2020 Jan;26(1):44-49. doi: 10.1016/j.bbmt.2019.09.005. Epub 2019 Sep 10. Biol Blood Marrow Transplant. 2020. PMID: 31518644 Free article. Clinical Trial.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG. Voorhees PM, et al. Among authors: sborov dw. Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288. Blood. 2020. PMID: 32325490 Free PMC article. Clinical Trial.
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
Lonial S, Nooka AK, Thulasi P, Badros AZ, Jeng BH, Callander NS, Potter HA, Sborov D, Zaugg BE, Popat R, Degli Esposti S, Byrne J, Opalinska J, Baron J, Piontek T, Gupta I, Dana R, Farooq AV, Colby K, Jakubowiak A. Lonial S, et al. Among authors: sborov d. Blood Cancer J. 2021 May 26;11(5):103. doi: 10.1038/s41408-021-00494-4. Blood Cancer J. 2021. PMID: 34039952 Free PMC article. Clinical Trial.
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Usmani SZ, Karanes C, Bensinger WI, D'Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG. Usmani SZ, et al. Among authors: sborov d, d souza a. Leukemia. 2021 Dec;35(12):3526-3533. doi: 10.1038/s41375-021-01262-w. Epub 2021 May 28. Leukemia. 2021. PMID: 34050260 Free PMC article. Clinical Trial.
91 results